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Background/Aims: Irritable bowel syndrome (IBS) is 
a troublesome disease. Some strains of probiotics re-
portedly exert remarkable immunomodulatory effects, 
and so we designed a prospective double-blind 
randomized placebo-controlled clinical study to assess 
their effects in Korean adults with IBS. Methods: IBS 
patients who met Rome III criteria were randomly as-
signed to receive composite probiotics or placebo. A 
total of 20 billion lyophilized bacteria were ad-
ministered twice daily for 8 weeks. Primary outcome 
variables were symptom scores consisting of abdomi-
nal pain, flatulence, defecation discomfort, and sum of 
symptom scores. A visual analogue scale was used 
to quantify the severity. Secondary outcome variables 
consisted of the quality of life and bowel habits in-
cluding defecation frequency and stool form. Results: 
Thirty-six and 34 patients were randomized to the 
probiotics and placebo groups, respectively. Intention- 
to-treat analysis showed significant reductions in pain 
after 8 weeks of treatment: −31.9 and −17.7 in the 
probiotics and placebo groups, respectively (p=0.045). 
The reductions in abdominal pain, defecation dis-
comfort, and sum of scores were more significant in 
58 patients with a score of at least 3 on the baseline 
stool-form scale. Conclusions:  Composite probiotics 
containing  Bifidobacterium bifidum BGN4,  Lactobacillus 
acidophilus  AD031, and other species are safe and 
effective, especially in patients who excrete normal or 
loose stools. (Gut and Liver 2009;3:101-107)
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INTRODUCTION
  Irritable bowel syndrome (IBS) is one of the most trou-
blesome diseases, which has the high prevalence as well 
as the chronic and recurrent course. In United States, IBS 
is known as the most common gastrointestinal disease 
and comprises 25 to 50% of all referrals to gastro-
enterologists,
1 and the prevalence of IBS has estimated to 
range 9% to 22% of the population.
2 In Korea, Park et al.
3 
reported the prevalence of IBS increased up to 16.8%. A 
few effective medicines such as cisapride, tegaserod and 
alosetron have been withdrawn from the market because 
of their serious adverse drug reactions. There is no specif-
ic treatment that has proven to be effective and safe in 
the patients with IBS.
  Through previous studies, IBS is known to be asso-
ciated with low-grade inflammation of the intestinal mu-
cosa regardless of whether to be the post-infectious sub-
type or not.
4,5 Although a few clinical studies to evaluate 
the immunomodulatory effect of probiotics showed symp-
tom relief in IBS patients, probiotics are not yet used 
widely in daily practice.
6-8 A s  g l o b a l  c o m p e t e t i o n  f o r  
searching more potent strain was heating up, a well-de-
signed clinical study becomed necessary to validate the ef-
fect of promising probiotics. Two in vitro studies using 
some strains of Bifidobacterium bifidum demonstrated that 
they were effective in inhibiting lipopolysaccharide (LPS)- 
induced inflammation, and the later study showed high 
LPS-binding capacity and inhibition of inflammatory 
cytokine.
9,10 Kim et al.
11 reported Bifidobacterium bifidum 
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on the control of inflammatory bowel disease (IBD) using 
a mouse model. With composite probiotics including 
Bifidobacterium bifidum BGN4 and other promising strains, 
we designed a prospective double-blind randomized place-
bo-controlled clinical study to prove the effect in the 
Korean adults with IBS. 
MATERIALS AND METHODS
1. Study population
  Patients were recruited from the outpatient department 
of Seoul National University Hospital. The study protocol 
was approved by the institutional review board. The in-
clusion criteria were as follows: age of 19-75 years, both 
male and female, and the presence of previous gastro-
intestinal symptoms suggestive of IBS using the Rome III 
criteria regardless of its subtypes. All participants gave a 
written informed consent form that had been approved by 
the institutional review board.
    The exclusion criteria were as follows: previous ab-
dominal surgery except appendectomy and hernia repair, 
history of IBD, current use of medications that may alter 
gastrointestinal motility, antibiotics or probiotics within 2 
weeks prior to the 1-week run-in period, severe co-mor-
bidity such as cancer, heart or renal failure, gynecologic 
disease etc., and pregnant or breast-feeding female. 
2. Study design
  We performed a parallel-group, double-blinded, random-
ized, placebo-controlled clinical study. A 1-week run-in 
observation period was followed by an 8-week treatment 
period. During this entire 9-week period, participants 
were required to record a daily diary of bowel habits con-
sisting of frequency and consistency. A questionnaire on 
irritable bowel symptoms such as abdominal pain, flat-
ulence and defecation discomfort was recorded at base-
line, 4th and 8th week after treatment. A questionnaire 
on quality-of-life (QOL) was recorded at baseline and 8th 
week.
  Primary outcome variables were symptom scores that 
consisted of abdominal pain, flatulence, defecation dis-
comfort and the sum of these three symptom scores. 
Laborious evacuation, tenesmus and urgency were in-
cluded in questionnaire for defecation discomfort. A 100 
mm visual analogue scale (VAS) was used to measure the 
severity of each symptom as scores ranging from 0 to 
100. When participants were asked to mark VAS after 
treatment, they could look at his or her previous marks. 
Secondary outcome variables were bowel habits that re-
corded using a validated Bristol stool form scale and QOL 
that recorded using a RAND 36-item health survey.
12-14 
3. Administration of probiotics
  Composite probiotics were composed of 4 viable lyophi-
lized bacteria species: Bifidobacterium bifidum BGN4; 
Bifidobacterium lactis AD011; Lactobacillus acidophilus AD031; 
and  Lactobacillus casei IBS041. Each probiotic packet with 
equal doses of 4 strains contained total 20 billion lyophi-
lized bacteria in a powder form. A placebo packet con-
taining skim milk powder looked identical to the compo-
site probiotics. Both probiotics and placebo were supplied 
by BIFIDO Co., Ltd., Hongchun, Korea. Each participant 
in both treatment groups received one packet orally with 
water within 10 minutes after a meal, twice daily (40 bil-
lion lyophilized bacteria per day) for 8 weeks.
4. Randomization
  We used blocked randomization method with block size 
4 or 6 and generated permutations at random using SPSS 
for Windows 12.0.1 (SPSS Inc., Chicago, IL, USA) pro-
vided by the medical research collaborating center at our 
institution that was independent of medical care. All par-
t i c i p a n t s  w e r e  a s s i g n e d  a n  a l l o c a t i o n  n u m b e r  i n  r e g u l a r  
sequence after confirmation of enrollment. For adherence 
to double-blind design, the allocation number was match-
ed to a randomization code successively by a clinical trial 
pharmacist. Till completion of the study, the clinical trial 
pharmacist kept the randomization table sealed off. 
5. Sample size calculation and statistical analyses
  On the ground of previous reports, we assumed the re-
sponse rates would be 70% in probiotics group and 40% 
in placebo group.
8 The response was defined as reduction 
of symptom score by at least 50% after treatment. Other 
assumptions for sample size calculation were as follows: 
alpha error 0.05; statistical power 0.8; drop-out rate 0.05; 
and one-sided test. We used the equation below, the 
s a m p l e  s i z e  w a s  e s t i m a t e d  a s  3 5  p e r  g r o u p  i n  v i e w  o f  
drop-out rate. 
( )
2
2
2 2 1 1 ) 1 ( ) 1 ( ) 1 ( 2
d
p p p p Z p p Z
N
− + − + −
=
β α
p1 (response rate in probiotics group)=0.7 
p2 (response rate in placebo group)=0.4
p=(p1+p2)/2=0.55
d=p2−p1=0.3
Zα=1.65 (alpha error=0.05)
Zβ=0.84 (statistical power=0.8) 
 
  All data were collected by a single trained interviewer 
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Table 1. Characteristics of Subjects
   Characteristics Probiotics (n=36) Placebo (n=34)
Age (years)
  Mean (±SE) 36±2 38±3
  Range 21-69 22-72
Females (n) 11  12 
Baseline score (±SE)
  Pain  50.3 (±3.5)  46.9 (±3.4)
  Flatulence  49.9 (±3.6)  49.3 (±4.8)
  Defecation   53.5 (±4.0)  47.0 (±5.1)
  Sum 153.6 (±8.9) 143.2 (±9.0)
  QOL 104.6 (±1.1) 104.7 (±1.4)
Defecation frequency* 8.1  7.1 
Stool consistency
†
4.2 4.0 
IBS subtype
‡
  Diarrhea  19  13 
  Constipation  7   7 
  M i x e d    2    4
  Unsubtyped  8  10 
QOL, quality-of-life.
*Bowel movements per week, 
†
Bristol stool form scale; 
average for a week, 
‡
Rome III criteria.
Table 2. Symptom Scores Analyzed over 4 and 8-week Treat-
ment Period (Two-sided T-test Using the 0.05 Significance 
Level)
Probiotics Placebo p-value
ITT population (n=70) 
Pain Baseline  50.3  46.9 0.487
Δ 4 week −23.9 −10.9 0.061
Δ 8 week −31.9 −17.7 0.045
Flatulence Baseline  49.9  49.3 0.928
Δ 4 week −18.5 −18.4 0.982
Δ 8 week −27.0 −21.3 0.437
Defecation Baseline  53.5  47.0 0.311
Δ 4 week −29.2 −13.5 0.043
Δ 8 week −30.5 −18.4 0.122
Sum Baseline 153.6 143.2 0.413
Δ 4 week −71.7 −42.8 0.115
Δ 8 week −89.5 −57.5 0.064
Subgroup* (n=58)
Pain Baseline  51.2  46.2 0.315
Δ 4 week −26.9 −5.8 0.004
Δ 8 week −33.9 −13.3 0.006
Flatulence Baseline  49.2  47.8 0.826
Δ 4 week −19.6 −13.0 0.463
Δ 8 week −26.7 −15.9 0.175
Defecation Baseline  53.2  45.0 0.826
Δ 4 week −30.4 −10.6 0.013
Δ 8 week −30.0 −14.5 0.064
Sum Baseline 153.6 138.9 0.288
Δ 4 week −76.9 −29.4 0.010
Δ 8 week −90.6 −43.6 0.010
*Baseline Bristol stool form scale ≥3.
of run-in phase) was considered as baseline in all stat-
istical analyses. The “intent-to-treat” (ITT) population 
was defined as all participants who received probiotics or 
placebo for at least one week and visited our hospital for 
the interview once or more. Efficacy analysis was per-
formed in the ITT population. χ
2-test was performed to 
test response rates. As symptom score, QOL score, con-
sistency and frequency were all continuous variables, 
two-sided T-test was performed using the 0.05 signifi-
cance level. 
RESULTS 
  Between 1 November 2007 and 29 February 2008, 76 
patients were screened. 5 patients (6.5%) were ineligible 
as they did not meet the inclusion criteria, and 1 with-
d r e w  c o n s e n t .  A  t o t a l  o f  7 0  p a t i e n t s  w e r e  e n r o l l e d ,  3 6  
were randomized to probiotics group and 34 to placebo. 
Demographic and clinical characteristics were similar be-
tween the two groups (Table 1).
1. Compliance and concomitant medications
  Of 36 participants assigned to probiotics, 35 com pleted 
treatment as planned. One participant withdrew from the 
study due to an exacerbation of abdominal pain asso-
ciated with IBS. Another one participant, who was as-
signed to placebo, withdrew from the study due to an ex-
acerbation of constipation associated with IBS. Both with-
drawn participants were included in efficacy analysis 
based on the definition of ITT population; symptom 
scores and the bowel habit were imputed using the mean 
value of the group. A total of 68 participants completed 
the study. Overall compliance was more than 98% in 
both groups. 
  E l e v e n  o f  7 0  p a r t i c i p a n t s  r e q u i r e d  c o n c o m i t a n t  m e d i -
cations during the study, 3 in probiotics group and 8 in 
placebo. Ten participants, except one in probiotics group 
who was prescribed a common cold medication, used lo-
peramide, prokinetics, pain killers, histamine 2 receptor 
antagonists, proton pump inhibitors or laxatives due to 
an exacerbation of bowel symptoms. According to ITT 
principle, all the eleven patients were included in 
analyses. 
2. Symptom scores, QOL and bowel habits
    ITT analyses showed significant reductions of pain 
score after 8 weeks of treatment (−31.9 in probiotics 
group vs. −17.7 in placebo [p=0.045]) and defecation 
discomfort after 4 weeks of treatment (−29.2 vs. −13.5, 
respectively [p=0.043]). Subgroup analyses in 58 patients 
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Fig. 1. Pain and flatulence scores analyzed over 4- and 8-week treatment periods.
showed more significant reductions of pain score after 8 
weeks of treatment (−33.9 in probiotics group vs. −13.3 
in placebo [p=0.006]), defecation discomfort score after 4 
weeks of treatment (−30.4 vs. −10.6, respectively [p= 
0.013]), and sum of scores after 8 weeks of treatment 
(−90.6 vs. −43.6, respectively [p=0.010]) (Table 2, Figs. 
1 and 2). Subgroup analyses in 10 patients, whose base-
line Bristol stool form scales were below 3, did not show 
any significant changes. Response rate evaluation through 
χ
2-test failed to show significant changes as follows: re-
sponse rate in pain were 64% in probiotics group vs. 44% 
in placebo (p=0.248), response rate in defecation dis-
comfort were 58% vs. 41% (p=0.317), and response rate 
in sum of scores were 56% vs. 50% (p=0.750), respec-
tively. There was no significant change of QOL and bowel 
habits including defecation frequency and stool con-
sistency in both groups (Table 3). 
3. Adverse events
  There was no serious adverse event associated with 
treatments. Twelve of 70 participants reported mild ad-
verse events including common cold, headache, cystitis, 
low back pain etc. The number of adverse events per 
group was 8, same in both groups.
DISCUSSION
  Symptoms of IBS are subjective and there is no ob-
jective test that can measure severity of IBS. Symptom 
scores are popular methods for assessing severity of IBS, 
but these can be influenced by an interviewer as well as 
patients themselves. Strict double-blind design is essential 
to assess the effect of probiotics on symptoms in IBS 
patients. We could perform a strict double-blinded study 
by the help of MRCC and clinical trial pharmacists for 
random code generation and code-matching. Patel et al.
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Fig. 2. Defecation discomfort and sum of scores analyzed over 4- and 8-week treatment periods.
Table 3. Analysis of Quality of Life, Defecation Frequency and 
Stool Consistency over 8-week Treatment Period (Two-sided 
T-test Using the 0.05 Significance Level)
Probiotics Placebo p-value
ITT population (n=70) 
QOL Baseline 104.6 104.7 0.957
Δ 8 week  −1.3   −1.1 0.887
Frequency
†
Baseline  8.1  7.1 0.414
Δ 8 week  −0.1  0.1 0.817
Consistency
‡
Baseline  4.2  4.0 0.453
Δ 8 week  0.2  −0.1 0.430
Subgroup* (n=58)
QOL Baseline 104.4 104.8 0.876
Δ 8 week  −1.5   −1.7 0.919
Frequency
†
Baseline  8.7  7.9 0.553
Δ 8 week  −0.6   −0.2 0.689
Consistency
‡
Baseline  4.6 4.4 0.374
Δ 8 week  −0.1   −0.4 0.241
QOL, quality-of-life.
*Baseline Bristol stool form scale ≥3, 
†
Bowel movements per 
week, 
‡
Bristol stool form scale; average for a week.
reported that placebo response in IBS studies ranged from 
16% to 71% via meta-analysis. In our study, the overall 
p l a c e b o  e f f e c t  w a s  3 5 %  t h a t  i s  c o m p a r a b l e  w i t h  m a n y  
other IBS studies and seems to be a matter of course in 
double-blinded study.
16-18 Strong points of our study de-
sign include strict double-blind design, data collection by 
a single trained interviewer, relatively large number of 
study population (n=70) and no need of data processing 
including adjusting and standardization. 
  Although Kim et al.
6,7 reported that VSL #3 reduced 
flatulence scores in the patients with IBS, probiotics have 
not been the standard treatment of IBS due to the follow-
ing reasons: need of huge dose of probiotics (VSL #3, 
4.5×10
11 bacteria/packet), relatively low efficacy (10 mm 
difference from placebo on 100 mm scale) and no effect 
in abdominal pain and urgency. A recent report showed 
that low dose of one strain (Bifidobacterium infantis 35624, 
1×10
8 bacteria/capsule) reduced symptom scores in IBS 
patients,
8 and the result suggested that the effect of pro-
biotics for IBS was dependent on a specific strain as well 106   Gut and Liver, Vol. 3, No. 2, June 2009
as dose. Some strains of Lactobacillus w e r e  k n o w n  t o  b e  
effective in controlling IBS symptoms.
19 A paper studying 
an alteration of gut microbiota reported that Lactobacillus 
sequences were absent in stool from IBS patients, con-
trary to healthy control.
20 Regarding the reduction of ab-
dominal pain by probiotics, a recent study demonstrated 
that one strain of Lactobacillus acidophilus induced the 
expression of mu-opioid and cannabinoid receptors in in-
testinal epithelial cells of rodents and mediated analgesic 
functions in the gut.
21 As described in introduction, con-
sidering the immunomodulatory effect of Bifidobacterium 
bifidum BGN4 and potential benefit of Lactobacillus sp. we 
selected study medication as composite probiotics com-
posed of Bifidobacterium bifidum BGN4, Bifidobacterium lactis 
AD011,  Lactobacillus acidophilus AD031 and Lactobacillus 
casei  IBS041. All of them are original strains that were 
collected from Koreans and have been never used in clin-
ical study.
    We demonstrated that selected composite probiotics 
were effective in IBS patients (ITT population, n=70) as 
follows: pain reduced by 64% in probiotics group vs. 38% 
in placebo (p=0.045), and defecation discomfort reduced 
by 55% vs. 29% (p=0.043), respectively. In agreement to 
a previous report, probiotics were more effective in pa-
tient who excreted mainly normal or loose stool (baseline 
Bristol stool form scale ≥3, n=58) as follows: pain re-
duced by 66% in probiotics group vs. 29% in placebo 
(p=0.006), defecation discomfort reduced by 57% vs. 
24% (p=0.013), and sum of scores reduced by 59% vs. 
31% (p=0.010), respectively.
8 In contrast to many reports 
that probiotics showed minimal or no effect on abdominal 
pain, we demonstrated the beneficial effect in the treat-
ment of IBS symptoms including abdominal pain using 
composite probiotics containing Bifidobacterium bifidum 
BGN4 and Lactobacillus acidophilus AD031.
6-8,16  Although 
Sinn et al.
22 reported that two strains of Lactobacillus acid-
ophilus  reduced abdominal pain by 20% more than place-
bo in IBS patients, we could demonstrate superior effect 
of probiotics on abdominal pain up to 37% over placebo. 
As compared with VSL #3 that showed effectiveness on 
overall score up to 16% over placebo, our composite pro-
biotics were more effective on overall score up to 28% 
over placebo.
6
  χ
2-test was performed to test the response which was 
defined as reduction of symptom score by at least 50% 
after treatment in this study, but it could not show sig-
nificant change. Data loss was inevitable in the process of 
converting symptom scores into responder status which 
was classified as yes or no, and it seemed to be the rea-
son of low sensitivity of χ
2-test. By simultaneously doing 
parametric analyses over changes of individual scores after 
treatment, we could demonstrate the effect of probiotics 
accurately. 
  Although the analyses on bowel habits showed slight 
decrease of frequency, there was no statistically sig-
nificant change between two groups, which might be due 
to low power of this study. A previous study showed nor-
malization of frequency in Bifidobacterium-treated group 
through post hoc analyses (n=182) using data stratified by 
baseline bowel movements per day.
8 On the basis of fur-
ther large-scale studies, probiotics are expected to be re-
vealed as effective in correction of bowel habits. 
  In conclusion, composite probiotics containing Bifido-
bacterium bifidum BGN4, Bifidobacterium lactis AD011, 
Lactobacillus acidophilus AD031 and Lactobacillus casei 
IBS041 were safe and effective, especially in patients who 
excreted mainly normal or loose stool. 
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